Introduction {#Sec1}
============

Schizophrenia is characterized by well-known "positive" and "negative" symptoms and by less recognized cognitive deficits in executive functions, working memory, and attention (Bowie and Harvey [@CR3]). These cognitive deficits are present at the onset of illness, persist without remission throughout most of patients' lives, and may precede the development of "positive" symptoms (Brewer et al. [@CR4]). Flexibility in response to a change in attentional set toward stimuli is controlled by the prefrontal cortex (PFC) and is commonly assessed in patients using the Wisconsin Card Sorting Test (WCST; Grant and Berg [@CR17]; Elliott et al. [@CR11]). A poor WCST performance is observed not only in schizophrenics but also in patients with frontal lobe damage (Pantelis et al. [@CR40]).

The impairments in executive functions observed in WCST in humans can be investigated using a rodent version of the attentional set-shifting task (ASST) developed by Birrell and Brown ([@CR2]). The ASST requires animals to initially learn a rule and form "an attentional set" within the same stimulus dimension, by discriminating between, e.g., the odors associated with food reward. During the extra-dimensional (ED) shift, the crucial and most difficult part of the test, the subjects have to rapidly switch their attention to a new and previously irrelevant stimulus dimension and to discriminate between, e.g., the media covering the food reward. Although an increasing number of laboratories have successfully used the ASST in rats, most of the attempts to adapt this procedure for use in mice have failed to demonstrate an ED shift deficit (Colacicco et al. [@CR7]; Laurent and Podhorna [@CR29]; Zhuo et al. [@CR50]; Levi et al. [@CR30]). Only one procedure, described by Garner et al. ([@CR14]) and replicated with slight modification by Papaleo et al. ([@CR41]), has shown a significant extra-dimensional shift (EDS) phase deficit in this species. However, our laboratory was unable to demonstrate an ED shift impairment even with these modifications, and therefore, the *first goal* of the present study was to establish the conditions allowing for the measurement of reliable set-shifting in mice.

Converging lines of evidence indicate the involvement of glutamate NMDA transmission in schizophrenia. A single dose of an NMDA receptor antagonist, such as phencyclidine (PCP) or ketamine, induces symptoms of acute psychosis in healthy volunteers (Luby [@CR33]; Javitt and Zukin [@CR23]). Because these symptoms are indistinguishable from some symptoms of schizophrenia (Krystal et al. [@CR26]), antagonists of NMDA receptors are routinely used in preclinical research as a pharmacological model of this psychosis (Olney and Farber [@CR38]; Jentsch and Roth [@CR24]). The acute administration of ketamine impairs attentional set-shifting as measured by the WCST in healthy humans (Krystal et al. [@CR27]) and in the rat (Nikiforuk et al. [@CR37]). Therefore, the *second goal* of the present study was to investigate the ketamine-induced impairment of ASST in mice.

Compared to conventional antipsychotics, relatively novel atypical compounds, such as sertindole, display an advantageous profile of pro-cognitive actions in schizophrenia. A recent multi-center, randomized, double-blinded clinical trial indicated a beneficial effect of sertindole on executive functions in patients with schizophrenia (Gallhofer et al. [@CR13]); this medication also reduced the debilitating effects of ketamine in the Stroop task in healthy volunteers (Vollenweider et al. [@CR46]). Several preclinical studies have shown that sertindole reduces or reverses the impairing effects of subchronic PCP treatment (Rodefer et al. [@CR42]; Broberg et al. [@CR5]; Goetghebeur and Dias [@CR16]) and of an acute dose of ketamine (Nikiforuk et al. [@CR37]) in the rat ASST. An obligatory step in the validation of a given procedure relies on the demonstration of a positive effect of the medication previously found to be effective in similar conditions. The *third goal* of the present study was to investigate whether sertindole could reverse ketamine-induced deficits in the mouse version of the ASST.

NMDA receptors are heteromers composed of an obligatory NR1 (mouse zeta 1) subunit and of at least one type of the NR2 (NR2A--NR2D; mouse epsilon 1--4) subunits (Laube et al. [@CR28]; Schorge and Colquhoun [@CR43]). The type of NR2 subunit constituting the NMDA receptor affects its physiological and pharmacological properties (Monaghan and Larsen [@CR34]; Loftis and Janowsky [@CR32]). In addition, the brain distribution of NR2 subunits is not uniform (Monyer et al. [@CR35]; Wenzel et al. [@CR48]); although NR2A messenger RNA (mRNA) is distributed particularly in the cerebral cortex, hippocampus, and cerebellum, the NR2B transcript is selectively present in the forebrain with a high level of expression in the cerebral cortex, hippocampus, septum, caudate--putamen, and olfactory bulb. The NR2C mRNA is expressed predominantly in the cerebellum, and the NR2D transcript is detected in the thalamus, brain stem, and olfactory bulb. The NR2C and NR2D transcripts are found in a subset of hippocampal neurons, which are most likely interneurons (Ozawa et al. [@CR39]).

This pattern of distribution suggests that subunit-specific NMDA antagonists may have differential effects under various physiological and pathological conditions (Skolnick et al. [@CR44]). Although ketamine is regarded as an NR2-unspecific antagonist (Dravid et al. [@CR8]), recent data indicate that it mainly affects NR1/2C and NR1/2D NMDA receptors (Kotermanski and Johnson [@CR25]). Due to its antagonistic action at hippocampal NMDA receptors, ketamine may cause cortical disinhibition, which is relevant to some symptoms of schizophrenia, including cognitive inflexibility (Greene [@CR18]; Homayoun and Moghaddam [@CR22]; Lisman et al. [@CR31]). In contrast, the NR2B-selective antagonist, CP-101,606 (traxoprodil), under certain test conditions, improves cognitive flexibility as assessed by the five-choice serial reaction time task (5-CSRT; Higgins et al. [@CR21]). Therefore, the *fourth goal* of the present study was to investigate the effects of an NR2B-selective antagonist alone and in combination with ketamine in the ASST procedure. We used the Ro 25-6981 compound \[(aR,bS)-a-(4-hydroxyphenyl)-b-methyl-4-(phenylmethyl)-1-piperidinepropanol hydrochloride\] that is characterized by a \>5,000-fold selectivity for NR2C/NR2B over NR2C/NR2A subunits of the NMDA receptor, use-dependent binding properties and neuroprotective effects against glutamate toxicity (Fischer et al. [@CR12]).

Materials and methods {#Sec2}
=====================

Ethics {#Sec3}
------

The experiments were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Ethics Committee for Animal Experiments, Institute of Pharmacology.

Animals {#Sec4}
-------

The studies were performed on male C57Bl/6J mice (Institute of Pharmacology breeding facility, originating from the Jackson Laboratories and purchased from Charles-River, Germany) weighing approximately 24 g and being approximately 7 to 8 weeks old at the start of the experiment. The mice were housed in standard laboratory cages under standard colony A/C-controlled conditions: room temperature of 21 ± 2°C, humidity of 40% to 50%, and a 12-h light/dark cycle (lights on at 06:00). The mice were individually housed and mildly food deprived (2.9 g of food pellets per day), with ad libitum access to water for 1 week prior to testing. Mice were food restricted throughout the experiment to maintain approximately 85% of their initially body weight. Behavioral testing was performed during the light phase of the light/dark cycle. Different groups of animals were used in different drug experiments.

Attentional set-shifting task procedure {#Sec5}
---------------------------------------

The experiments were performed according to the procedure for mice described by Garner et al. ([@CR14]) and Papaleo et al. ([@CR41]) with some modifications. The mice were tested in a black acrylic U-shaped maze apparatus (*W* × *L*, 39 × 39 cm) with a wire grid floor. The starting compartment provided an entrance via guillotine doors into two identical testing compartments. A bowl with water was placed in the starting compartment to allow mice free access to water throughout the whole training procedure. The food reward (1/8 of Honey Nut Cheerio, Nestle®) was presented in containers (glass dishes, 5 cm in diameter, 3 cm in depth). The containers were defined by a pair of cues with two stimulus dimensions: different kinds of digging media and distinct odors (2 μl of a flavoring essence, Dr. Oetker®, Poland, on a piece of the blotting paper fixed to the external wall of a glass dish prior to use). Different containers were used for each combination of the digging medium and odor. Stimulus dimensions are shown in Table [1](#Tab1){ref-type="table"}. Table 1Pairs of different stimuli used in the mouse version of the ASSTDimensionExemplar pairsOdorOrangeLemonSpicyCreamArrackAlmondVanillaRumMediumFine gravelCrumpled tissueCardboardBamboo sticksBeadsAluminum ballsPlasticPolystyrene

The entire study consisted of several experiments. Each experiment was performed on three consecutive days with training sessions 1 and 2 on the 2nd and 3rd days (Table [2](#Tab2){ref-type="table"}). Table 2Detailed illustration of the present ASST procedurePhaseDimensionDiscrimination 1Discrimination 2Session 1SDMediaFine gravel vs. *beads* CDMediaOrangeArrackOrangeArrackFine gravel*BeadsBeads*Fine gravel CDRMediaOrangeArrackOrangeArrack*Fine gravel*BeadsBeads*Fine gravel* IDSMediaLemonAlmondLemonAlmond*Crumpled tissue*Aluminum ballsAluminum balls*Crumpled tissue* IDSRMediaLemonAlmondLemonAlmondCrumpled tissue*Aluminum ballsAluminum balls*Crumpled tissue Session 2IDS2MediaSpicyVanillaSpicyVanilla*Cardboard*PlasticPlastic*Cardboard* IDSR2MediaSpicyVanillaSpicyVanillaCardboard*PlasticPlastic*Cardboard EDSOdors*Cream*Rum*Cream*RumBamboo sticksPolystyrenePolystyreneBamboo sticks EDSROdorsCream*Rum*Cream*Rum*Bamboo sticksPolystyrenePolystyreneBamboo sticksFor each trial, mice were presented with either discrimination 1 or 2. In this example at the SD phase, all digging dishes had no odor, and the subjects had to choose the beads as the correct digging medium (in *italics*). Note that the stimuli are the same for CD and CDR, for IDS and IDR, and for EDS and EDSR

Habituation (day 1) {#Sec6}
-------------------

On the first day of testing, mice were habituated to the apparatus, containers, and food reward for 5 min. The four phases of shaping were then initiated; the first three phases with two trials each and the fourth phase with three trials were performed sequentially. During each trial, the mouse was placed in the starting compartment, and the guillotine door was raised to allow entry to the test compartment with the containers filled with the food reward. During the first phase, the food reward was placed at the bottom of an empty container. For the next phase, the containers were filled with 0.5 cm of wood shavings, and the food reward was placed on top of the filling. In the third phase, the reward was placed under a thin layer of wood shavings. In the final phase, the food reward was buried under 2 cm of wood shavings. Once the mice retrieved the food reward, they were allowed to consume it before being returned to the starting compartment.

Session 1 (2nd day) and session 2 (3rd day) {#Sec7}
-------------------------------------------

Each mouse was trained to discriminate between pairs of containers that differed in odor and/or the media covering the food reward. This training was performed during two sessions, which consisted of several phases with several trials. During each trial, the animal was placed in the starting compartment, and the guillotine door was raised to give the mouse access to two containers, only one of which contained the food reward. The food reward was buried under the surface of distinct digging media. The first three trials of each session were "free", meaning that even after an incorrect choice, the door remained open, and the mouse was allowed to investigate and collect the food reward from the opposite container. On subsequent trials, the door was closed upon the animal's entry to the compartment. If the mouse started to dig in the un-baited container (i.e., the container without the food reward), an error was recorded, the trial was terminated, and the mouse was returned to the starting compartment. Each mouse had to reach a criterion of eight correct discriminations out of ten consecutive trials to complete each phase. The inter-trial interval was approximately 5 s, and the interval between consecutive phases in a given session was approximately 45 s.

We followed the protocol of Papaleo et al. ([@CR41]) by inserting additional phases (IDS2 and IDSR2). However, in contrast to the protocols of Papaleo et al. ([@CR41]) and Garner et al. ([@CR14]), we divided the whole ASST procedure into two sessions. The reason for using a two-session procedure was that the mice appeared satiated when we attempted to complete all of the phases of testing in 1 day. Therefore, session 1 consisted of a warm-up habituation trial (identical to the last trial of the habituation session) and five phases: (1) simple discrimination (SD), (2) compound discrimination (CD), (3) compound discrimination reversal (CDR), (4) intra-dimensional shift (IDS), and (5) intra-dimensional shift reversal (IDSR). The overall testing time for one animal during this session was approximately 60 to 70 min. Session 2 also consisted of a warm-up habituation trial and four phases: (1) intra-dimensional shift 2 (IDS2), (2) intra-dimensional shift reversal (IDSR2), (3) EDS, and (4) extra-dimensional shift reversal (EDSR). The overall testing time for one animal during this session was approximately 40 to 50 min.

Thus, the mice were exposed to a series of increasingly difficult discriminations during which they discriminated within a dimension (the media covering the food reward) that was relevant from the SD phase until the EDS phase. At the EDS phase, the mouse had to start discriminating within a new stimulus dimension (odors), and the previously relevant dimension (media) became irrelevant. This schedule was used for all of the subjects and was based on preliminary results that demonstrated a tendency for better performance when the sequence of dimension change was from the media to odors (data not shown). An example of the entire task is shown in Table [2](#Tab2){ref-type="table"}.

Drugs {#Sec8}
-----

Ketamine (10% aqueous solution of 115.34 mg/ml, Biowet, Poland) and Ro 25-6981 compound \[(aR,bS)-a-(4-hydroxyphenyl)-b-methyl-4-(phenylmethyl)-1-piperidinepropanol hydrochloride\] (Sequoia, UK) were dissolved in distilled water. Sertindole (Sigma-Aldrich, Germany) was dissolved in a minimum amount of 0.1 M hydrochloric acid and diluted with water. Drugs were administered before each of the two sessions. Therefore, the same animal received drug treatment twice: ketamine at 50 min, 3 h or 24 h (IP), the Ro 25-6981 compound at 30 min (IP), and sertindole at 120 min (PO). The ketamine "24-h" animals received the drug approximately 1 h after the last trial of habituation and approximately 1 h after session 1. All of the compounds were administered in a volume of 10 ml/kg, and the doses were chosen based on in-house data and published literature (Higgins et al. [@CR21]; Rodefer et al. [@CR42]).

Statistics {#Sec9}
----------

The following parameters were measured for each mouse: the number of trials to criterion, the number of errors to criterion, and the time to reach criterion, which was defined as eight correct choices out of ten consecutive trials. Statistical analyses were performed with Statistica 8.0 for Windows. The data from sessions 1 and 2 were calculated separately using repeated measures ANOVAs. Whenever significant interactions between the treatment conditions and the phase of a session were found, the data were analyzed with Newman--Keuls post hoc test; *P* \< 0.05 was deemed significant.

Results {#Sec10}
=======

Modification of the ASST procedure: general remarks {#Sec11}
---------------------------------------------------

The modification of the protocols of Garner et al. ([@CR14]) and Papaleo et al. ([@CR41]) produced reliable set-shifting in mice because in all replications, the subjects required significantly more trials to reach the criterion during the EDS than during the IDS2 phase of the task. The interaction factor between treatment conditions and the session phase for all of the experiments' session 1 measures, including trials, errors, and time to criterion, yielded insignificant results.

Time-related effects of ketamine on ASST performance {#Sec12}
----------------------------------------------------

As assessed by the interaction factors between treatment condition and the phase of a given session, ketamine (10 mg/kg, 3 or 24 h before the test) changed neither the number of trials and errors nor the time to reach the criterion at any of the discrimination phases (Fig. [1a--c](#Fig1){ref-type="fig"}). In contrast, when administered 50 min before testing, ketamine significantly increased the number of trials (*F*(9, 84) = 2.72, *P* \< 0.01; Fig. [1a](#Fig1){ref-type="fig"}) and errors (*F*(9, 84) = 2.86, *P* \< 0.01; Fig. [1c](#Fig1){ref-type="fig"}) to criterion during the EDS phase. Although the time to criterion in this group was increased (Fig. [1b](#Fig1){ref-type="fig"}), the interaction (treatment × phase) for session 2 yielded insignificant results. Fig. 1**a**--**c** Relationship between the time of ketamine administration and attentional set-shifting performance in mice. Ketamine (10 mg/kg) was administered 50 min and 3 or 24 h before both sessions. *N* = 8 mice per treatment condition. Data are presented as the mean ± SEM. Symbols: \**P* \< 0.05 vs. vehicle, ^**i**^*P* \< 0.05 vs. IDS2 phase, ^**k**^*P* \< 0.05 vs. ketamine 10 mg/kg group at 50 min (the standard ketamine treatment); Newman--Keuls post hoc test

Dose-related effects of ketamine on ASST performance {#Sec13}
----------------------------------------------------

Ketamine (10 and 20 mg/kg, administered 50 min before the test) dose-dependently, significantly, and specifically increased the number of trials (*F*(6, 66) = 17.49, *P* \< 0.001; Fig. [2a](#Fig2){ref-type="fig"}), errors (*F*(6, 66) = 8.22, *P* \< 0.001; Fig. [2b](#Fig2){ref-type="fig"}), and the time to criterion (*F*(6, 66) = 9.04, *P* \< 0.001; Fig. [2c](#Fig2){ref-type="fig"}) during the EDS phase. In all three measures, the effects of 20 mg/kg ketamine were significantly stronger than the effects of 10 mg/kg. Fig. 2**a**--**c** Dose-dependent effects of ketamine on the attentional set-shifting task in mice. Ketamine (10 or 20 mg/kg) was administered 50 min before both sessions. *N* = 8--9 mice per treatment. Data are presented as the mean ± SEM. Symbols: \**P* \< 0.05 vs. vehicle, ^**i**^*P* \< 0.05 vs. IDS2 phase, ^**k**^*P* \< 0.05 vs. ketamine 10 mg/kg group; Newman--Keuls post hoc test

Effects of sertindole on ketamine-induced deficits in the ASST {#Sec14}
--------------------------------------------------------------

Similar to the two earlier experiments, 10 mg/kg of ketamine administered 50 min before the sessions increased both the number of trials (*F*(3, 84) = 2.62, *P* \< 0.05; Fig. [3a](#Fig3){ref-type="fig"}) and errors (*F*(3, 84) = 2.67, *P* \< 0.05; Fig. [3c](#Fig3){ref-type="fig"}) to criterion during the EDS phase. Sertindole + ketamine treatment decreased these measures to the levels of the control group, and they were significantly lower compared to the ketamine alone treatment. Sertindole (2.5 mg/kg) did not change the number of trials or errors to criterion during the EDS phase compared with the vehicle-treated and sertindole + ketamine-treated groups (Fig. [3a, c](#Fig3){ref-type="fig"}). In this set of data, the time to criterion measure (Fig. [3b](#Fig3){ref-type="fig"}) was not affected by any of the treatments. Fig. 3Effects of sertindole on ketamine-induced deficits in the attentional set-shifting task in mice. Sertindole (2.5 mg/kg) and ketamine (10 mg/kg) were administered 2 h and 50 min before both sessions, respectively (*N* = 7--9 mice per treatment). Data are presented as the mean ± SEM. Symbols: \**P* \< 0.05 vs. vehicle, ^**i**^*P* \< 0.05 vs. IDS2 phase, ^**k**^*P* \< 0.05 vs. ketamine 10 mg/kg group; Newman--Keuls post hoc test

Dose-related effects of Ro 25-6981 on ASST performance {#Sec15}
------------------------------------------------------

Ro 25-6981, administered 30 min before both sessions at 10 mg/kg, but not at 3 mg/kg, significantly and specifically facilitated performance during the EDS phase. The higher dose decreased the number of trials (*F*(6, 63) = 4.97, *P* \< 0.001; Fig. [4a](#Fig4){ref-type="fig"}) and errors (*F*(6, 63) = 4.27, *P* \< 0.01; Fig. [4c](#Fig4){ref-type="fig"}) to criterion compared to the vehicle-treated group and compared to the group treated with the lower dose. The time to criterion measure (Fig. [4b](#Fig4){ref-type="fig"}) was not affected by these treatments. Fig. 4**a**--**c** Effects of Ro 25-6981 on attentional set-shifting task performance in mice. Ro 25-6981 (3 or 10 mg/kg) was administered 30 min before both sessions (*N* = 8 mice per treatment). Data are presented as the mean ± SEM. Symbols: \**P* \< 0.05 vs. vehicle, ^**i**^*P* \< 0.05 vs. IDS2 phase, ^**\#**^*P* \< 0.05 vs. Ro 25-6981 at 3 mg/kg; Newman--Keuls post hoc test

Effects of Ro 25-6981 on ketamine-induced deficits in the ASST {#Sec16}
--------------------------------------------------------------

Ketamine (10 mg/kg) increased the number of trials to criterion during the EDS phase, but the Ro 25-6981 treatment alone (10 mg/kg) decreased this measure compared to the vehicle-treated group (*F*(3, 84) = 8.72, *P* \< 0.001; Fig. [5a](#Fig5){ref-type="fig"}), confirming our earlier findings. The administration of Ro 25-6981 to ketamine-pretreated mice decreased the number of trials to criterion during the EDS phase compared to the vehicle- and ketamine-treated groups (Fig. [5a](#Fig5){ref-type="fig"}). A similar pattern of effects was observed for the errors to criterion measure; however, this statistical analysis yielded insignificant results (*P* = 0.10; Fig. [5c](#Fig5){ref-type="fig"}). Ketamine (10 mg/kg) prolonged the time to criterion during the EDS phase (see also Fig. [2](#Fig2){ref-type="fig"}), and the ketamine + Ro 25-6981 treatment decreased this measure compared to the ketamine alone group (*F*(3, 84) = 4.09, *P* \< 0.01; Fig. [5b](#Fig5){ref-type="fig"}). Similar to the earlier experiment, the Ro 25-6981 treatment shortened the time to criterion compared to the vehicle-treated group, but statistical analysis yielded insignificant differences. Fig. 5**a**--**c** Effects of Ro 25-6981 on ketamine-induced deficits in the attentional set-shifting task in mice. Ro 25-6981 (10 mg/kg) and ketamine (10 mg/kg) were administered 30 and 50 min before both sessions, respectively (*N* = 8 mice per treatment). Data are presented as the mean ± SEM. Symbols: \**P* \< 0.05 vs. vehicle, ^**i**^*P* \< 0.05 vs. IDS2 phase, ^**k**^*P* \< 0.05 vs. ketamine 10 mg/kg group; Newman--Keuls post hoc test

Discussion {#Sec17}
==========

The present study demonstrated a procedure of attentional set-shifting in mice capable of revealing a deficit during the EDS phase, which was further impaired by ketamine administration. We confirmed that the atypical antipsychotic sertindole alleviated ketamine-induced cognitive deficits. In addition, the present data suggest that the NR2B subunit-selective NMDA antagonist Ro 25-6981 not only facilitated ASST performance during the EDS phase but also reversed ketamine-induced cognitive inflexibility.

Only two published modifications of the primary ASST procedure for rats (Birrell and Brown [@CR2]) have successfully demonstrated significant EDS phase impairment in mice (Garner et al. [@CR14]; Papaleo et al. [@CR41]). Because mice were unable to complete the test in 1 day under our experimental conditions, we divided the procedure into two sessions and included additional phases (IDS2 and IDSR2). As pointed out by Garner et al. ([@CR14]), like reversal phases (CDR and IDSR), these additional phases serve to strengthen the cognitive set formation. This outcome was manifested by a general improvement in performance during the phases ranging from CD to IDSR2 followed by a poorer EDS phase performance, which is regarded as the primary measure of set-shifting. Under these conditions, we demonstrated reliable set-shifting in mice because, in all replications (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, and [5](#Fig5){ref-type="fig"}), the subjects required significantly more trials to reach the criterion during the EDS phase than during the IDS2 phase of the task. A drawback of the 2-day protocol is that the investigated compound has to be administered twice, but the relatively short duration of the test session could be considered as a potential advantage for the investigation of compounds characterized by a short half-life.

The present work confirms the results of Nikiforuk et al. ([@CR37]) demonstrating that, in the rat ASST, ketamine produces specific deficits in cognitive flexibility after a single dose given 50 min before the test and extends these findings to the mouse species. Although these studies cannot be compared directly, the observed effect was dose dependent; the higher dose of ketamine (20 mg/kg) more severely impaired the task performance compared to the lower dose (10 mg/kg). It was also time dependent; the ED shift deficit was demonstrated at 50 min, but not 3 or 24 h, following drug administration. The latter observation somewhat contrasts with the findings of Egerton et al. ([@CR10]), demonstrating that a single dose of PCP tested 24 h after administration produced an ED shift impairment. However, different NMDA receptor antagonists were used, and the studies were performed in a different species. Notably, in clinical experiments, WCST impairment is observed 40 min after ketamine infusion (Krystal et al. [@CR27]), and ketamine-induced psychotomimetic effects, as measured by the Brief Psychiatric Rating Scale, disappeared within 2 h after infusion (Berman et al. [@CR1]; Zarate et al. [@CR49]). Therefore, the current protocol appears to be a promising pharmacological tool for modeling mouse cognitive inflexibility. Its predictive validity is based on the inhibitory effects of sertindole (Fig. [3](#Fig3){ref-type="fig"}), which also reduced the impairing effects of PCP-like compounds in the rat ASST in former studies (Rodefer et al. [@CR42]; Broberg et al. [@CR5]; Goetghebeur and Dias [@CR16]; Nikiforuk et al. [@CR37]) and alleviated the cognitive impairments associated with schizophrenia (Gallhofer et al. [@CR13]) and ketamine administration in healthy volunteers (Vollenweider et al. [@CR46]).

The major finding of this set of experiments concerns the pro-cognitive effects of the NMDA NR2B subunit-selective antagonist Ro 25-6981 in the mouse ASST. These effects were shown by the reversal of the ketamine-induced cognitive deficit (Fig. [5](#Fig5){ref-type="fig"}) and by cognitive improvement in mice treated with Ro 25-6981 only (Fig. [4](#Fig4){ref-type="fig"}). The pro-cognitive effects of the NR2B-selective antagonist are in sharp contrast to the PCP-like antagonists, and to our knowledge, this is the first demonstration of an NMDA antagonist-induced pro-cognitive action in the ASST. The effects of NR2B-selective antagonists on cognitive functions are complicated. The Ro 63-1908 does not affect performance in the Morris water maze and delayed matching to position task (DMTP) performance, though in 5-CSRT Ro 63-1908 produces an increase in premature responses, and in differential reinforcement of low-rate 24 s (DRL24) task, it reduces the inter-response time, suggesting an impairment of response inhibition (Higgins et al. [@CR20]). Although traxoprodil does not affect spatial learning (Guscott et al. [@CR19]), Ro 25-6981 disrupts spatial reversal learning and enhances perseveration in the Morris water maze (Duffy et al. [@CR9]). Consistent with the latter report, NMDA 2B subunit over-expression results in better performance in learning and memory tasks, like novel object recognition, the Morris water maze, and the t-maze, in mice (Tang et al. [@CR45]; Cao et al. [@CR6]) and rats (Wang et al. [@CR47]).

Nonetheless, in tasks specifically assessing cognitive flexibility, like the 5-CSRT, both traxoprodil and Ro 25-6981 (3--30 mg/kg) increase premature responding and response speed with no error trade-off similar to Ro 63-1908. At a short inter-trial interval, Ro 63-1908 reliably improved performance, both in terms of response speed and accuracy, and traxoprodil improves accuracy and increases response speed in the DMTP task (Higgins et al. [@CR21]). These authors conclude that selective NR2B NMDA antagonists promote impulsive-type responding that---under certain test conditions, such as a higher event rate of stimulus presentation---results in an improvement of task performance. Somewhat similar results have been reported by Gilmour et al. ([@CR15]), who show that NR2B-specific antagonists increase instrumental output in a series of variable interval schedules of reinforcement in an operant task. Our data appear to confirm these findings because the treatment with Ro 25-6981 not only reduced the number of trials to criterion (Fig. [4a](#Fig4){ref-type="fig"}) but also reduced, albeit insignificantly, the time required to complete the EDS phase of the set-shifting task (Figs. [4b](#Fig4){ref-type="fig"} and [5b](#Fig5){ref-type="fig"}).

The present data cannot offer a convincing explanation of the mechanism for the pro-cognitive action of Ro 25-6981. The ASST does not allow for the measurement of all of the parameters that are typically recorded in 5-CSRT and is a relatively simple procedure with a remarkably lower workload. Nonetheless, we may speculate that the Ro 25-6981-induced reduction in the number of trials to criterion and in the time to complete the EDS phase resembles a similar improvement in performance (response speed and accuracy) as the improvements found in the 5-CSRT (Higgins et al. [@CR21]). The ketamine-induced inhibition of hippocampal NMDA receptors may enhance the firing rate of glutamatergic PFC neurons and impair PFC-dependent functions, including cognitive flexibility (Greene [@CR18]; Homayoun and Moghaddam [@CR22]; Lisman et al. [@CR31]). A high density of the NR2B subunit within the PFC, including infra-limbic regions (Wenzel et al. [@CR48]), confirmed by autoradiography with \[3H\]-Ro 25-6981 (Mutel et al. [@CR36]), suggests that the compound exerted its actions in the PFC. It is likely that the unique localization of the NR2B-containing NMDA receptors allows for the reversal of the ketamine-induced cognitive deficit in ASST via blockade of glutamatergic cortical disinhibition. Future studies will reveal the precise mechanism of the pro-cognitive action of this NR2B-selective NMDA antagonist.
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